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An important trend in current toxicology is the replacement,
reduction, and reﬁnement of the use of experimental animals (the
3R principle). We propose a model in which in vivo genotoxicity
and short-term carcinogenicity assays are integrated with F344
gpt delta transgenic rats. Using this model, the genotoxicity of
chemicals can be identiﬁed in target organs using a shuttle vector
l EG10 that carries reporter genes for mutations; short-term
carcinogenicity is determined by the formation of glutathione
S-transferase placenta form (GST-P) foci in the liver. To begin
validating this system, we examined the genotoxicity and
hepatotoxicity of structural isomers of 2,4-diaminotoluene
(2,4-DAT) and 2,6-diaminotoluene (2,6-DAT). Although both
compounds are genotoxic in the Ames/Salmonella assay, only
2,4-DAT induces tumors in rat livers. Male F344 gpt delta rats
were fed diet containing 2,4-DATat doses of 125, 250, or 500 ppm
for 13 weeks or 2,6-DATat a dose of 500 ppm for the same period.
The mutation frequencies of base substitutions, mainly at G:C
base pairs, were signiﬁcantly increased in the livers of 2,4-DAT–
treated rats at all three doses. In contrast, virtually no induction of
genotoxicity was identiﬁed in the kidneys of 2,4-DAT–treated rats
or in the livers of 2,6-DAT–treated rats. GST-P–positive foci were
detected in the livers of rats treated with 2,4-DAT at a dose of
500 ppm but not in those treated with 2,6-DAT. Integrated
genotoxicity and short-term carcinogenicity assays may be useful
for early identifying genotoxic and nongenotoxic carcinogens in
a reduced number of experimental animals.
Key Words: gpt delta transgenic rat; diaminotoluenes;
genotoxicity; carcinogenicity; 3R principle.
Transgenic rodent models have advanced the ﬁeld of
in vivo genotoxicity studies (Nohmi and Masumura, 2005;
Nohmi et al., 2000). In these models, k phage DNA
carrying reporter genes for mutations are integrated into
the chromosomes of transgenic rodents; the phage DNA is
r e t r i e v e di np h a g ep a r t i c l e sb yin vitro packaging reactions.
The rescued phages are introduced into Escherichia coli
cells, and mutants that were generated in the rodents are
selected. With the shuttle vector system, one can examine
the mutagenicity of chemicals in any rodent organ or tissues,
including germ cells (Eastmond et al., 2009; Hashimoto
et al., 2009). In addition, the mutants recovered from the
rodents can be characterized by DNA sequencing (Heddle
et al., 2000). Transgenic genotoxicity assays are a reliable
method for determining whether genotoxicity is involved in
chemical carcinogenicity in the target organs of rodents
(Thybaud et al., 2003).
In 1996, we developed the novel transgenic mouse gpt delta
for in vivo genotoxicity assays (Nohmi et al., 1996). These
mice have approximately 80 copies of k EG10 DNA at a single
site in chromosome 17 of C57 BL/6J mice (Masumura et al.,
1999). A feature of this transgenic mouse is that two mutant
selections can be performed instead of just one, to identify
a wider spectrum of in vivo mutations: gpt selection to identify
point mutations such as base substitutions and frameshift
mutations and Spi
  selection to identify deletion mutations.
Because of their sensitivity to deletion-type mutations, gpt
delta mice have been utilized for radiation biology, cancer
research, and regulatory toxicology (Aoki et al., 2007;
Masumura et al., 2002; Shibata et al., 2009; Xu et al., 2007).
In 2003, we established gpt delta rats in a Sprague-Dawley
(SD) background by introducing k EG10 DNA into fertilized
SD rat eggs (Hayashi et al., 2003). This gpt delta rat carries
approximately ﬁve copies of k EG10 DNA at a single site in
chromosome 4 and is sensitive to induction of point mutations
and deletions by benzo[a]pyrene and potassium bromate
(Hayashi et al., 2003; Umemura et al., 2009).
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344 background by backcross of SD gpt delta rats with F344 rats
for 15 generations. We generated F344 gpt delta rats because
this background is frequently used for 2-year cancer bioassays.
In addition, glutathione S-transferase placenta form (GST-P)–
positive preneoplastic hepatic foci can be analyzed in the rats
(Ito et al., 2000). The results of bioassay using GST-P–positive
foci show good correlation with those of 2-year cancer bioassay
(Ito et al., 2000; Ogiso et al., 1985). Therefore, GST-P–positive
foci formation assay was used as short-term carcinogenicity
assay in this study. We hypothesized that we could integrate
a genotoxicity assay with a short-term carcinogenicity assay
utilizing GST-P foci in F344 gpt delta rats. This would reduce
the number of animals required for both assays and would allow
for examination of the relationship between genotoxicity and
preneoplastic lesion formation within the same organs and
tissues of chemically treated F344 gpt delta rats.
To begin validating this system, we examined the
in vivo genotoxicity and hepatotoxicity of 2,4-diaminotoluene
(2,4-DAT) and 2,6-diaminotoluene (2,6-DAT). The ﬁrst
chemical, 2,4-DAT, is used as an intermediate of the
production of toluene diisocyanate, which is a monomer for
the production of polyurethane, while 2,6-DAT is an in-
termediate of dyes, rubber chemicals, and various polymers
(NTP 1979, 1980). Although both are genotoxic in vitro
(Cunningham et al., 1989), only 2,4-DAT is carcinogenic in
the livers of female mice and male and female rats (NTP,
1979). 2,4-DAT also induces lymphoma in female mice and
mammary and subcutaneous tumors in rats. 2,6-DAT is not
carcinogenic in mice and rats, regardless of their sex (NTP,
1980). Previous studies with MutaMouse (Kirkland and
Beevers, 2006) and Big Blue mouse (Cunningham et al.,
1996) indicate that 2,4-DAT is mutagenic in the liver, while
2,6-DAT is not. However, the transgenic mice employed for
these studies were males, in which the hepatocarcinogenicity of
2,4-DAT is not observed. In addition, there are no reports on
in vivo gene mutations in rats. Thus, we decided to examine the
in vivo genotoxicity of both compounds in the liver, as
carcinogenic target organ of 2,4-DAT, and kidney, as non-
carcinogenic target, along with immunohistochemical analyses.
We chose 500 ppm as the highest dose for both DATs
according to the dose used in the National Toxicology Program
2-year cancer bioassay (NTP, 1979, 1980). We treated the rats
with chemicals for 13 weeks because this period is customarily
used to determine the appropriate doses for 2-year cancer
bioassays; furthermore, shorter term treatments (e.g., treat-
ments with potassium bromate for 5 weeks [Umemura et al.,
2006]), sometimes do not induce detectable mutations in vivo.
MATERIALS AND METHODS
Establishment of F344 gpt delta rats. All the animals were maintained at
Japan SLC (Shizuoka, Japan). The F344 gpt delta transgenic rat strain was
developed by backcrosses of the original SD gpt delta transgenic rat with wild-
type F344 rats. In brief, male SD gpt delta transgenic rat was mated with F344
female rat to produce an F1 generation. Offspring from the F1 generation were
mated with F344 rats to yield an F2 generation. All offspring from successive
backcrosses were examined for the possession of the gpt gene by PCR (Hayashi
et al., 2003). After 15 successive backcrosses, identity of the resulting rats to
F344 recipient is more than 99.9%. Thus, they were referred to as F344
gpt delta rats.
Chemicals. 2,4-DAT (purity 95%) and 2,6-DAT (purity 98%) were
purchased from Wako Pure Chemical Industries (Osaka, Japan). Diethylnitros-
amine (DEN) was obtained from Sigma-Aldrich Japan (Tokyo, Japan).
Bacterial reverse mutation test (Ames test). The mutagenic activities of
2,4-DAT and 2,6-DAT were assayed in a bacterial reverse mutation assay using
Salmonella typhimurium tester strains TA98 and YG1024, an O-acetyltransferase
(OAT)–overexpressing derivative. The test was conducted by the preincubation
method (Maron and Ames, 1983) in the presence or the absence of S9 mix. At
least two plates were used for each dose, and the mean values of the number of
revertants per plate were calculated. Chemicals were dissolved in dimethyl
sulfoxide, which was used as the negative control.
Animals, diet, and housing conditions. Male 6-week-old F344 gpt delta
transgenic rats were obtained from Japan SLC and housed ﬁve animals per
polycarbonate cage under speciﬁc pathogen-free standard laboratory
conditions: room temperature, 23C ± 2C; relative humidity, 60 ± 5%; with
a 12:12-h light-dark cycle; and free access to CRF-1 basal diet (Oriental Yeast
Company, Tokyo, Japan) and tap water. After a 1-week acclimation period, the
animals were used for the experiments.
Treatments of animals. The protocol for this study was approved by the
Animal Care and Utilization Committee of the National Institute of Health
Sciences. Thirty male F344 gpt delta rats were randomized by weight into six
groups. 2,4-DAT and 2,6-DAT were each mixed into Oriental CRF-1
powdered basal diet (Oriental Yeast Company) and stored at 4C in the dark
before use. Starting at 7 weeks of age, the rats were fed diets containing 0,
125, 250, or 500 ppm 2,4-DAT or 500 ppm 2,6-DAT for 13 weeks. There was
also a positive control group; these rats were received a once-a-week ip
injection of 20 mg/kg body weight DEN for 13 weeks. Parameters monitored
included clinical signs, body weight, and food intake. The highest dose of
2,4-DAT was reduced from 500 to 400 ppm at week 9 because the dose at
500 ppm reduced the body weight of rats at week 8. All the surviving animals
were killed under ether anesthesia at the end of the experiments. The liver and
kidneys were isolated from each animal and were immediately excised,
weighed, and cut into 2- to 3-mm-thick slices. The slices were ﬁxed in 10%
buffered formalin solution and routinely processed to parafﬁn blocks for
histopathological examination as well as immunohistochemistry. Hematoxylin
and eosin-stained tissue preparations cut from the blocks were examined by light
microscopy.
Micronucleus assay. At autopsy, 60 ll of peripheral blood was obtained
from the tail veins of all animals. The samples were processed according to the
instructions supplied with the MicroFlow
PLUS kit (Litron, Rochester, NY),
ﬁxed in ultra-cold methanol, and stored immediately after ﬁxation at  80C
until ﬂow cytometry analysis was performed. Approximately 20,000
reticulocytes were counted for each sample using Becton-Dickinson FACSCa-
libur ﬂow cytometer (Franslin Lakes, NJ) to detect the presence of micronuclei
(MNs).
Immunohistochemical procedures. Liver sections of 3-lm thickness were
treated with rabbit anti-rat GST-P antibody (1:1000; Medical & Biological
Laboratories, Nagoya, Japan) and monoclonal mouse anti-Ki67 (MIB-5)
antibody (1:50; Dako, Tokyo, Japan) (1:50), respectively. Areas and numbers
of GST-P–positive foci larger than 0.1 mm in diameter of the liver sections
were quantitatively measured with an image processor for analytical pathology
(IPAP-WIN; Sumika Technos Company, Osaka, Japan). To investigate
proliferative activity, we counted at least 1000 hepatocyte nuclei in each liver;
labeling indices were calculated as the percentage of cells positive for Ki67
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stored at  80C for subsequent mutation assays.
DNA isolation and in vitro packaging of k phage DNA. High–molecular-
weight genomic DNA was extracted from the liver and kidneys using the
RecoverEase DNA Isolation kit (Stratagene, La Jolla, CA). k EG10 phages
were rescued using Transpack Packaging Extract (Stratagene).
gpt Mutation assay. The assay was conducted according to previously
published methods (Nohmi et al., 1996). All the conﬁrmed gpt mutants
recovered from the livers were sequenced; identical mutations from the same
rat were counted as one mutant. The mutant frequencies of the gpt gene (gpt
MFs) in the liver and kidney were calculated by dividing the number of
conﬁrmed 6-thioguanine–resistant colonies by the number of rescued plasmids.
DNA sequencing of the gpt gene was performed with the BigDye Terminater
Cycle Sequencing Ready Reaction (Applied Biosystems, Foster City, CA) on
an ABI PRISM 310 Genetic Analyzer (Applied Biosystems).
Spi
  assay. The Spi
  assay was conducted according to previously
published methods (Masumura et al., 2002). To conﬁrm the Spi
  phenotype of
the candidates, suspensions were spotted on three types of plates on which
XL-1 Blue MRA, XL-1 Blue MRA P2, or WL95 P2 strains were spread with
soft agar. True Spi
  mutants, which made clear plaques on all of the plates,
were counted. Spi
  mutant lysates were obtained by infecting E. coli LE392
with the recovered Spi
  mutants. The lysates were used as templates for PCR
and sequencing analysis to determine the deleted regions (Masumura et al.,
2002). The Spi
  mutants were categorized into three classes: one base pair (bp)
deletions, deletions of more than 1 bp, and complex mutations. The entire
sequence of k EG10 is available at http://dgm2alpha.nihs.go.jp/default.htm.
Statistical analysis. The statistical signiﬁcance of the difference in the
value of MFs between treated groups and negative controls was analyzed by
Student’s t-test. A p value less than 0.05 denoted the presence of a statistically
signiﬁcant difference. Variances in values for body weight, organ weight, and
immunohistochemical data were examined by one-way ANOVA with
Dunnett’s multiple test to compare the differences between control and treated
groups.
RESULTS
Dietary Treatment with 2,4-DAT Induced Preneoplastic
Lesions in the Livers of F344 gpt Delta Rats
Dietary treatment with 2,4-DAT reduced body weight
signiﬁcantly at all three doses, while dietary treatment with
2,6-DAT did not (Supplementary table 1). Treatments with
2,4-DAT, but not 2,6-DAT, increased the relative weight of the
livers and kidneys in a dose-dependent manner. Hypertrophy
and vacuolar degeneration of hepatocytes was observed in the
livers of rats in the 2,4-DAT treatment groups (Fig. 1). Cell
proliferation was signiﬁcantly enhanced by 2,4-DAT at a dose
of 250 ppm but not by treatment with 2,6-DAT or other doses
of 2,4-DAT (Table 1). That labeling index was twofold higher
compared with that of basal diet group. GST-P–positive foci
were induced by treatment with 2,4-DAT at a dose of 250 or
500 ppm and by the positive control treatment with DEN
(Table 2). There were signiﬁcant differences in number of foci
and area of foci between rats treated with 2,4-DAT at 500 ppm
and those of the basal diet group and between rats treated with
DEN and the control group. No histopathological changes were
observed in the kidneys of rats that were fed 2,4-DAT or
2,6-DAT. These results suggest that 2,4-DAT, but not 2,6-
DAT, induced preneoplastic lesions in the livers of F344 gpt
delta rats.
Both 2,4-DAT and 2,6-DAT Induced Mutations In Vitro
We conﬁrmed that both 2,4-DAT and 2,6-DAT were
mutagenic in S. typhimurium strain TA98 in the presence of
S9 activation (Fig. 2). Treating cells with either of the DATs in
the absence of S9 mix did not produce any increase in the
number of revertants per plate. Similar, but less signiﬁcant,
results were obtained with another standard S. typhimurium
strain TA100 (Supplementary table 2). These observations
suggest that DAT metabolites were responsible for the
mutagenic effects. To explore the metabolic activation path-
ways in vitro, we employed strain YG1024, which over-
produces OAT, a phase II enzyme. Strain YG1024 detects
frameshift mutations because it was derived from strain TA98
(Watanabe et al., 1994). As shown in Figure 2, YG1024
exhibited enhanced sensitivity to the mutagenicity of both 2,4-
DAT and 2,6-DAT in the presence of S9 activation. The
mutagenicity of 2,6-DAT was similar to that of 2,4-DAT in the
presence of S9 activation (in strain TA98, 1036 vs. 1316 His
þ
revertants per plate at 625 lg of 2,4-DAT and 2,6-DAT,
respectively; in strain YG1024, 3460 vs. 3896 His
þ revertants
per plate at 156 lg of 2,4-DAT and 2,6-DAT, respectively).
FIG. 1. Histological comparison of rat livers treated with 0 ppm 2,4-DAT
(A), 125 ppm 2,4-DAT (B), 250 ppm 2,4-DAT (C), 500 ppm 2,4-DAT (D),
500 ppm 2,6-DAT (E), and DEN (F). Hepatotoxicity was observed in rats
administered 2,4-DAT and DEN. Bar ¼ 100 lm.
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presence of S9 activation in vitro and also that O-acetylation is
important for the metabolic activation.
In Vivo Mutagenicity of 2,4-DAT
For the initial in vivo genotoxicity assay, we examined MN
formation in the peripheral blood of F344 gpt delta rats treated
with 2,4-DAT or 2,6-DAT. However, no signiﬁcant increase in
MN frequency was observed in any of the treated groups
(Supplementary table 4).
Next, we examined the mutagenicity of the DATs in the
livers and kidneys of the rats. gpt MFs were signiﬁcantly
increased in the livers of 2,4-DAT–treated rats at all three doses
and in the DEN-positive control, compared to the control group
(Fig. 3, Supplementary table 3). No increases in MFs were
observed in the livers of 2,6-DAT–treated rats or in the
kidneys of either 2,4-DAT– or 2,6-DAT–treated rats. To
characterize the gpt mutations in the liver, we performed DNA
sequencing (Table 3). The predominant base substitutions were
G:C-to-A:T transitions and G:C-to-T:A and G:C-to-C:G trans-
versions in the 2,4-DAT–treated groups. In addition, base
substitutions at A:T bps were also induced. In the DEN-treated
positive control group, A:T-to-T:A transversions were the most
predominant type of mutation. Spi
  MFs in the liver were also
signiﬁcantly increased in 2,4-DAT treatment groups at doses of
250 and 500 ppm and in the DEN-treated group (Table 4).
They were not increased by treatment with 2,6-DAT. DNA
sequence analysis revealed that the speciﬁc mutant frequency
(SMF) of a  1 frameshift at run sequences such as GGGG in
the gam gene was increased more than fourfold after treatment
with 500 ppm 2,4-DAT, while the SMF of deletions of more
than two bps was not enhanced at this dose (Supplementary
table 5). Thus, most of the Spi
  mutations were  1 frameshift
mutations at run sequences, and large deletion mutations were
not signiﬁcantly induced by treatment with 2,4-DAT.
DISCUSSION
In the regulatory sciences, a default assumption is that
genotoxic carcinogens have no thresholds for their activities,
and thus, no acceptable daily intake can be set for these
chemicals when they are used as food additives, pesticides, or
veterinary medicines (Kirsch-Volders et al., 2000; Nohmi,
2008). It is thought that single molecules of genotoxic
compounds can induce mutations, and thus, genotoxic
carcinogens impose carcinogenic risks to humans even at very
low doses. However, how the genotoxicity of chemicals should
be deﬁned is not entirely clear. Currently, more than 200
genotoxicity assays have been proposed (Preston and
Hoffmann, 2007). Unsurprisingly, the results among the
various genotoxicity assays are inconsistent. The aromatic
amine structural isomers 2,4-DAT and 2,6-DAT are an
interesting reference pair that illustrates the inconsistency
between in vitro and in vivo results (Cunningham et al., 1989).
Both 2,4-DAT and 2,6-DAT are mutagenic in vitro in
S. typhimurium strains, but only 2,4-DAT is carcinogenic in
mice and rats (NTP, 1979).
In this study, we conﬁrmed in vitro genotoxicity with
S. typhimurium TA98 and YG1024 and explored in vivo
genotoxicity with F344 gpt delta rats. Both DATs were
mutagenic in the S. typhimurium strains in vitro when the S9
activation system was present (Fig. 2). In contrast, only
2,4-DAT was mutagenic in the livers of rats (Fig. 3, Table 4,
Supplementary table 4). Both gpt and Spi
  MFs in the liver
were signiﬁcantly increased in 2,4-DAT–treated rats compared
to those in the control group. We did not observe any increase
in gpt MFs in the livers of 2,6-DAT–treated rats or in the
kidneys of 2,4- or 2,6-DAT–treated rats (Fig. 3, Supplementary
table 4). Kidney may not have capacity to activate 2,4-DAT as
in the case of bone marrow (see below). We identiﬁed
preneoplastic lesions (i.e., GST-P–positive foci) in the livers of
rats treated with 250 and 500 ppm 2,4-DAT (Table 2) but not
in the livers of rats treated with 2,6-DAT. Generally,
proliferation is activated in cancer cells. Ki-67 is a nuclear
marker of cell proliferation and detectable in cells at all phases
of the cell cycles except G0 (Gerdes et al., 1983). The Ki-67
TABLE 1
Quantiﬁcation of Hepatocyte Proliferation
No. of
Rats
No. of Total
Nuclei
No. of
Ki-67–Positive
Nuclei Index
Basal diet 5 2170.8 ± 890.9 27.4 ± 8.1 0.013 ± 0.004
Basal diet (DEN) 5 1749.6 ± 729.2
a 73.8 ± 19.7 0.042 ± 0.009*
125 ppm 2,4-DAT 5 1700.2 ± 700.1
a 14.0 ± 6.6 0.008 ± 0.005
250 ppm 2,4-DAT 5 1436.4 ± 596.7
a 44.4 ± 10.5 0.031 ± 0.007*
500 ppm 2,4-DAT 5 1308.6 ± 537.6
a 20.4 ± 9.0 0.015 ± 0.006
500 ppm 2,6-DAT 5 2048.8 ± 860.8 17.8 ± 7.4 0.014 ± 0.004
aTotal number of nuclei was signiﬁcantly decreased compared to the basal
diet treatment group.
*Signiﬁcantly different from the basal diet group (p < 0.01).
TABLE 2
Quantiﬁcation of GST-P–Positive Foci
No. of Rats
No. of Foci
(No./cm
2)
Area of
Foci (mm
2/cm
2)
Basal diet 5 0.00 ± 0.00 0.000 ± 0.000
Basal diet (DEN) 5 78.92 ± 17.70** 1.924 ± 0.655**
125 ppm 2,4-DAT 5 0.00 ± 0.00 0.000 ± 0.000
250 ppm 2,4-DAT 5 1.19 ± 1.21 0.022 ± 0.023
500 ppm 2,4-DAT 5 6.05 ± 3.93* 0.502 ± 0.476*
500 ppm 2,6-DAT 5 0.00 ± 0.00 0.000 ± 0.000
*Signiﬁcantly different from the basal diet group (p < 0.05).
**Signiﬁcantly different from the basal diet group (p < 0.01).
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the association with liver and breast cancer outcome
(de Azambuja et al., 2007; Nolte et al., 1998). The increase
in Ki-67 index suggested the precancerous status of liver of rats
treated by 2,4-DAT (Table 1, Fig. 1). We conclude from these
results that genotoxicity assays (i.e., gpt and Spi
  assays) and
short-term carcinogenicity assays (i.e., GST-P–positive foci
formation) can be conducted with F344 gpt delta rats. Because
we observed genotoxicity in the target organ of carcinoge-
nicity, these results strongly suggest that the carcinogenicity of
2,4-DAT is due to genotoxic activities. Integration of the
genotoxicity assay with the pathological assay including
GST-P–positive foci formation in gpt delta rats could reduce
the number of animals necessary for these assays; this would
contribute to the adoption of the 3R (reduction, replacement, and
reﬁnement) principle for animal use in the life sciences (Balls,
1997). It should be mentioned, however, that GST-P–positive foci
formation often needs long treatment periods, for example, 16 and
24 weeks, respectively, for 2-amino-3,8-dimethylimidazo[4,5-f]-
quinoxaline and 2-acetylaminoﬂuorene (Bagnyukova et al., 2008;
Tsuda et al., 2003) and such long treatments may increase the risk
of false-positive results of mutations due to nongenotoxic
mechanisms caused by chronic toxicity, for example, tumor
induction and inﬂammatory responses (Thybaud et al., 2003).
Why do both 2,6-DAT and 2,4-DAT exhibit mutagenicity
in vitro? The inconsistency between in vitro and in vivo results
could be due to the different metabolic pathways of 2,6-DAT
in vitro and in vivo. It is plausible that a DAT amino group is
ﬁrst oxidized by a speciﬁc cytochrome P450 (e.g., CYP1A2),
and the resulting N-hydroxy group is further activated by OAT,
which leads to the generation of nitrenium ions that can bind to
DNA in vitro (Watanabe et al., 1994). In vitro, both DATs
were mutagenic only in the presence of S9 activation, and
strain YG1024, which overexpresses OAT, exhibited greater
sensitivity to the DATs than did strain TA98 (Fig. 2). Both
S. typhimurium strains possess GC repetitive sequences in the
hisD gene that serve as target sites for mutations. We speculate,
therefore, that 2,4-DAT could be activated in vivo via the
pathway described above and induce mostly guanine adducts in
DNA. In fact, it was reported that 2,4-DAT induces DNA
FIG. 2. Mutagenic activity of 2,4-DAT (A) and 2,6-DAT (B) in Salmonella typhimurium strains TA98 (circle) and YG1024 (rhombus). Filled circle and
rhombus assayed with S9 mix; open circle and rhombus assayed without S9 mix.
FIG. 3. MFs of gpt genes. Values represent mean SD (n ¼ 5). Signiﬁcant differences were observed in 2,4-DAT–treated livers compared to livers from rats fed
negative control basal diet. *p < 0.05.
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than does 2,6-DAT (Taningher et al., 1995). The sequence
analysis that we conducted indicates that most of the mutations
induced by 2,4-DAT at 500 ppm were guanine base
substitutions; that is, G:C-to-A:T, G:C-to-T:A, and G:C-to-C:G
(Table 3). 2,6-DAT might be more efﬁciently detoxicated than
2,4-DAT in vivo because its para site at position 4 can be
oxidized and subsequently conjugated by phase II enzymes
(Cunningham et al., 1989). Detoxication of 2,6-DAT by phase
II enzymes may be ineffective in vitro compared to in vivo.
Appropriate cofactors, for example, uridine 5#-diphosphoric
acid P2-b-D-glucopyranuronosyl ester for glucuronidation, may
be needed to effectively detoxify the active metabolites of
2,6-DAT in vitro. At present, however, we cannot rule out the
possibility that other factors, such as DNA repair, cell
proliferation, translesion DNA synthesis, or apoptosis, might
be involved in the differences in mutagenicity of 2,6-DAT
in vitro and in vivo.
In addition to the discrepancy between in vitro and in vivo
mutagenicity, neither 2,4-DAT nor 2,6-DAT was genotoxic in
the bone marrows of rats according to the MN assay
(Supplementary table 3). 2,4-DAT is also not mutagenic when
applied to MutaMouse skin (Kirkland and Beevers, 2006).
Thus, we suggest that the negative results of the MN assay may
be due to inefﬁcient metabolic activation of 2,4-DAT at
extrahepatic sites. Alternatively, the active metabolites gener-
ated in the liver may not reach the bone marrow. The poor
metabolic activation in extrahepatic sites and/or short half-lives
of the active metabolites may also account for the negative
results of the MN assay with DEN in the bone marrow
(Supplementary table 3). The MN assay is usually the ﬁrst
choice for in vivo genotoxicity assays in the development of
pharmaceuticals; our results indicate that rather than relying on
the MN assay in the bone marrow, genotoxicity should be
evaluated in multiple organs, including the target organs of
carcinogenicity.
The Spi
  assay is unique to gpt delta mice and rats and
identiﬁes deletion-type mutations (Nohmi et al., 2000).
Previous studies with gpt delta mice suggested that genotoxic
compounds and physical factors (e.g., radiation) induce
different types of deletion mutations in vivo (Nohmi and
Masumura, 2005). For example, heavy-ion radiation, ultravi-
olet B radiation, and mitomycin C induce large deletions in the
liver, epidermis, and bone marrow, respectively, at molecular
sizes of >1 kbp (Horiguchi et al., 2001; Masumura et al., 2002;
Takeiri et al., 2003). In contrast, aromatic amines such
as 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)
and aminophenylnorharman (APNH) induce  1 frameshift
mutations in runs of guanine bases in the colon and liver,
respectively (Masumura et al., 2000, 2003). We characterized
Spi
  mutants obtained from the livers of rats treated with
500-ppm 2,4-DAT and concluded that, like PhIP and APNH,
2,4-DAT induces mostly  1 frameshift mutations (Supple-
mentary table 5). These results suggest that Spi
  assay, as well
as the gpt assay, is useful for characterizing mutations, which
may constitute the molecular basis of chemically induced
carcinogenesis.
At the 2006 International Conference on Harmonization of
Technical Requirements for Registration of Pharmaceuticals for
Human Use meeting held in Yokohama, Japan, revisions of the
guidelines for a basic test battery of in vitro and in vivo
genotoxicity tests were discussed (Hayashi, 2008). The current
guidelines recommend two in vitro assays (Ames test and either
a mammalian chromosome aberration test or a mammalian gene
mutation test) plus one in vivo assay (usually MN test). Because
of the high rate of false positives with in vitro mammalian cell
assays (Kirkland et al., 2005), however, an alternative test
battery was proposed at the meeting (Hayashi, 2008). The new
battery is composed of one in vitro assay (Ames test) plus two
in vivo assays (MN test plus a second in vivo test such as
a transgenic assay or in vivo comet assay). It is possible to
choose the classical battery of two in vitro assays plus one
TABLE 3
Classiﬁcation of gpt Mutations in gpt Delta Rat Livers
Type of gpt
Mutation
Basal
Diet
125 ppm
2,4-
DAT
250 ppm
2,4-
DAT
500 ppm
2,4-
DAT
500 ppm
2,6-
DAT
Basal
Diet
(DEN)
No. % No. % No. % No. % No. % No. %
Base substitution
Transition
G:C / A:T 4 22 15 26 18 38 12 35 4 27 13 22
(CpG) (1) (6) (6) (3) (1) (3)
A:T / G:C 1 6 1 2 5 11 1 3 3 20 12 21
Transversion
G:C / T:A 4 22 16 28 12 26 6 18 4 27 3 5
G:C / C : G 16 7 1 2 49 7 2 1 00 00
A:T / T : A 00 59 49 13 17 2 3 4 0
A:T / C : G 16 47 36 13 00 7 1 2
Deletion
 1 4 2 2 35 12 26 17 00
>2 2 1 1 23 00 13 2 1 3 00
Insertion 1 6 3 5 0 0 1 3 0 0 0 0
Others 0 0 2 3 0 0 2 6 0 0 0 0
Total 18 100 58 100 47 100 34 100 15 100 58 100
TABLE 4
Spi
2 Mutant Frequency in Rat Livers
Treatment No. of Rats
Mutant Frequency (3 10
 6)
(Mean ± SD)
p Value
(t-test)
Basal diet 5 4.43 ± 1.99
Basal diet (DEN) 5 341.22 ± 180.91 0.002
125 ppm 2,4-DAT 5 8.20 ± 4.75 0.07
250 ppm 2,4-DAT 5 13.42 ± 4.83 0.003
500 ppm 2,4-DAT 5 15.98 ± 4.45 0.0004
500 ppm 2,6-DAT 5 5.49 ± 2.53 0.241
76 TOYODA-HOKAIWADO ET AL.in vivo assay instead of the alternative new battery. With the 3R
principle in mind, integration of in vivo genotoxicity assays and
a 28-day repeated dose toxicity assay was also discussed. In vivo
mutagenicity assays and an in vivo MN assay can be integrated
into a 28-day repeated dose toxicity study when transgenic
rodents are used (Thybaud et al., 2003). In this study, we found
that an in vivo genotoxicity assay and a short-term bioassay for
liver carcinogenesis using GST-P–positive foci as an end point
of preneoplastic lesions can be conducted with F344 gpt delta
rats. Integration of the two assays using transgenic rats may
further facilitate adoption of the 3R principle in regulatory
toxicology.
SUPPLEMENTARY DATA
Supplementary data are available online at http://toxsci
.oxfordjournals.org/.
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